Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Tardive Dyskinesia

Tardive Dyskinesia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Tardive Dyskinesia

11 trials tracked for Tardive Dyskinesia: 8 in phase 3 or 4 and 7 with published results. The most-cited published study has 334 citations.

11Trials tracked
8Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 1 Phase 3 7 Phase 2 3
  1. Phase 3 Addressing Involuntary Movements in Tardive Dyskinesia Completed · 334 cited
  2. Phase 3 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed · 253 cited
  3. Phase 3 Reducing Involuntary Movements in Participants With Tardive Dyskinesia Completed · 47 cited
  4. Phase 3 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Completed · 13 cited
  5. Phase 3 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed · 10 cited
  6. Phase 3 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed · 7 cited
Show 5 more trials
  1. Phase 3 Aim to Reduce Movements in Tardive Dyskinesia Completed · 3 cited
  2. Phase 4 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Completed
  3. Phase 2 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Completed
  4. Phase 2 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) Completed
  5. Phase 2 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Ingrezza Sprinkle (valbenazine) for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease
Neurology FDA Approval
FDA Approves Ingrezza Sprinkle (valbenazine) for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease FDA approves a new sprinkle version of Ingrezza for two movement disorders
The FDA has approved Ingrezza Sprinkle, a VMAT2 inhibitor, for the treatment of adults with tardive dyskinesia and chorea associated with Hu…
FDA approves sprinkle form of Ingrezza to treat involuntary movements in adults with tardive dyskinesia or Huntington's disease chorea.
FDA Apr 10, 2026